NASDAQ:GANX - Gain Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.00
  • Forecasted Upside: 292.16 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$7.65
▼ -0.09 (-1.16%)

This chart shows the closing price for GANX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gain Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GANX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GANX

Analyst Price Target is $30.00
▲ +292.16% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Gain Therapeutics in the last 3 months. The average price target is $30.00, with a high forecast of $30.00 and a low forecast of $30.00. The average price target represents a 292.16% upside from the last price of $7.65.

This chart shows the closing price for GANX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Gain Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/5/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/31/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/31/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/29/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2021BTIG ResearchInitiated CoverageBuy$30.00High
4/12/2021OppenheimerInitiated CoverageOutperform$30.00High
(Data available from 9/28/2016 forward)

News Sentiment Rating

1.10 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/2/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/1/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/31/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/30/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/29/2021
  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/28/2021

Current Sentiment

  • 5 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Gain Therapeutics logo
Gain Therapeutics, Inc., a development stage biotechnology company, engages in developing various therapeutics to treat diseases caused by protein misfolding. It focuses rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, treating the underlying disease. It is developing structurally targeted allosteric regulator candidates in various preclinical studies to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.
Read More

Today's Range

Now: $7.65
Low: $7.65
High: $7.72

50 Day Range

MA: $8.06
Low: $7.01
High: $9.49

52 Week Range

Now: $7.65
Low: $6.90
High: $17.93

Volume

269 shs

Average Volume

104,113 shs

Market Capitalization

$90.86 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Gain Therapeutics?

The following sell-side analysts have issued reports on Gain Therapeutics in the last year: BTIG Research, Oppenheimer Holdings Inc., and Zacks Investment Research.
View the latest analyst ratings for GANX.

What is the current price target for Gain Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Gain Therapeutics in the last year. Their average twelve-month price target is $30.00, suggesting a possible upside of 287.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting GANX will reach $30.00 in the next twelve months. Oppenheimer Holdings Inc. has the lowest price target set, forecasting a price of $30.00 for Gain Therapeutics in the next year.
View the latest price targets for GANX.

What is the current consensus analyst rating for Gain Therapeutics?

Gain Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GANX will outperform the market and that investors should add to their positions of Gain Therapeutics.
View the latest ratings for GANX.

How do I contact Gain Therapeutics' investor relations team?

Gain Therapeutics' physical mailing address is 4800 HAMPDEN LANE SUITE 200, BETHESDA MD, 20814. The company's listed phone number is 301-500-1556 and its investor relations email address is [email protected] The official website for Gain Therapeutics is www.gaintherapeutics.com.